1. Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer

2. Clinical investigators (CI) 200620072008 Mean52%50%45% Approximately what percent of your patients with Stage II colon cancer receive adjuvant chemotherapy? Practicing oncologists (PO) 200620072008 Mean46%42%34%

3. Phase III randomized study of oxaliplatin, leucovorin calcium and fluorouracil with or without bevacizumab in patients with resected Stage II colon cancer FOLFOX + bevacizumab FOLFOX Eligibility Stage II (T3-4, N0, M0) with paraffin- embedded tumor specimen available * Patients are stratified according to disease stage (IIA versus IIB), microsatellite stability status (microsatellite stable [MSS] or microsatellite instable [MSI]) and presence or absence of heterozygosity at chromosome 18q. Patients deemed to be at high risk based on these molecular parameters are randomly assigned to one of two treatment arms (arms I and II), whereas patients at low risk are assigned to arm III. High risk* R Observation Protocol ID: ECOG-E5202 Target Accrual: 3,610 (Open) Low risk*

4. Phase III randomized study of oxaliplatin, leucovorin calcium and fluorouracil with or without bevacizumab in patients with resected Stage II colon cancer Study Contacts Eastern Cooperative Oncology Group Al Benson, MD, FACP, Protocol Chair Tel: 312-695-6180 Peter O’Dwyer, MD, BCh, Protocol Co-Chair Tel: 215-662-7606 Email: peter.odwyer@uphs.upenn.edu Source: NCI Physician Data Query, November 2008.

5. Clinical investigators Practicing oncologists Have you used Peter Ravdin’s Adjuvant! Online program for colon cancer? % answering yes 64%49% With approximately how many patients during the past year have you used Peter Ravdin’s Adjuvant! Online program for treatment of colon cancer? Median 820

6. Clinical investigators Practicing oncologists Approximately what percent of your patients with Stage II and III colon cancer do you think have a solid understanding of the following after consulting with you? Risks of adjuvant chemotherapy Mean 75%66% Benefits of adjuvant chemotherapy Mean 75%74%

7. Clinical investigators Practicing oncologists Which of the following, if any, is your preferred 5-FU + leucovorin + oxaliplatin regimen in the adjuvant setting? Modified FOLFOX6 72%51% FOLFOX4 4%28% FOLFOX6 4%17% Modified FOLFOX7 16%3% I do not use FOLFOX or FLOX in the adjuvant setting 0%1% Other 4%0%

8. Clinical investigators Practicing oncologists When administering oxaliplatin-containing chemotherapy in the adjuvant setting, how often do you generally administer intravenous calcium and magnesium for neuroprotection? Always 0%7% Usually 20%13% Sometimes 40%28% Rarely 20%22% Never 20%30%

9. Clinical investigators Practicing oncologists Which adjuvant chemotherapy regimen, if any, are you most likely to recommend for this patient at the following ages? FOLFOX100%83% FOLFOX + bevacizumab 0%11% Other chemotherapy0%6% 65-year-old patient Case 1: Adjuvant Therapy for Patients with Stage III Colon Cancer Woman in average health T3 tumor in the left descending colon 15/25 lymph nodes positive

10. Clinical investigators Practicing oncologists Which adjuvant chemotherapy regimen, if any, are you most likely to recommend for this patient at the following ages? FOLFOX60%32% FOLFOX + bevacizumab 0%3% Capecitabine28%34% 5-FU/LV (infusion or bolus) 8%21% Other chemotherapy4%7% No systemic therapy0%3% Case 1: Adjuvant Therapy for Patients with Stage III Colon Cancer Woman in average health T3 tumor in the left descending colon 15/25 lymph nodes positive 85-year-old patient

11. Clinical investigators Practicing oncologists Have you used bevacizumab off protocol in the adjuvant setting? % answering yes 12%14% (For those answering yes): In approximately how many patients have you used bevacizumab in the adjuvant setting in the past year? Median 46

12. AVANT adjuvant study: A Phase III randomized trial comparing FOLFOX to FOLFOX with bevacizumab to CAPOX with bevacizumab in patients with resected colon cancer [FOLFOX + bevacizumab] x 6 months followed by bevacizumab x 6 months FOLFOX x 6 months [CAPOX + bevacizumab] x 6 months followed by bevacizumab x 6 months Target Accrual: 3,450 (Closed) Protocol IDs: UCLA-0412086-01, ROCHE-BO17920A, NCT00112918 Eligibility High-risk Stage II or III colon cancer Curative surgery within the past four to eight weeks No clinically significant cardiovascular disease* R * Cerebrovascular accident within the past six months; myocardial infarction within the past year; uncontrolled hypertension while on chronic medication; unstable angina; NYHA Class II-IV heart failure; serious cardiac arrhythmias that require medication. A cardiac monitoring plan is included in this study.

13. AVANT adjuvant study: A Phase III randomized trial comparing FOLFOX to FOLFOX with bevacizumab to CAPOX with bevacizumab in patients with resected colon cancer Study Contact Joel Hecht, MD Tel: 888-798-0719 Source: NCI Physician Data Query, November 2008.

14. Clinical investigators Practicing oncologists Practicing oncologists should be discussing the potential impact on risk of recurrence of the following with patients diagnosed with colon cancer: Exercise Agree 76%68% In between 16%26% Disagree 8%6%

15. Clinical investigators Practicing oncologists Practicing oncologists should be discussing the potential impact on risk of recurrence of the following with patients diagnosed with colon cancer: Diet Agree 60%66% In between 28%30% Disagree 12%4%